Back to Journals » Drug Design, Development and Therapy » Volume 16

Lycium barbarum Polysaccharide Prevents Cisplatin Induced MLTC-1 Cell Apoptosis and Autophagy via Regulating Endoplasmic Reticulum Stress Pathway [Retraction]

Authors Yang F, Wei Y, Liao B, Wei G, Qin H, Pang X, Wang J

Received 22 March 2022

Accepted for publication 22 March 2022

Published 25 March 2022 Volume 2022:16 Pages 799—800

DOI https://doi.org/10.2147/DDDT.S367469



Yang F, Wei Y, Liao B, et al. Drug Des Devel Ther. 2018;12:3211–3219.

The Editor and Publisher of Drug Design, Development and Therapy wish to retract the published article. Concerns were raised following the authors request to change western blot data in Figure 4D. The authors provided a replacement image for Figure 4D, however they failed to adequately explain why they wished to change the images. In addition, the authors could not provide the original data for the western blots shown in Figure 4D or for any of the other western blot images shown in Figures 2A and 3C. It was determined the findings reported in the article were unreliable and a retraction was requested. The authors were notified of this decision.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted.”

This retraction relates to this paper

Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.